路透社报道
2026年2月25日 美国东部时间下午6:15 更新于1小时前
（图片说明：2020年8月29日，美国马里兰州怀特橡树的美国食品药品监督管理局（FDA）总部外的标识。路透社/Andrew Kelly/资料图片 [获取授权，新标签页打开]）
- 公司
- [美国食品药品监督管理局]关注
2月25日（路透社）- 美国食品药品监督管理局（FDA）周三表示，其顾问委员会定于3月12日开会，讨论并就2026-2027流感季使用的流感疫苗毒株组成提出建议。
订阅路透社健康动态新闻通讯，了解最新的医学突破和医疗趋势。[点击此处]注册。
- 去年，该会议被取消，这是卫生部长小罗伯特·F·肯尼迪（Robert F. Kennedy Jr.）领导下与疫苗相关的顾问小组遭受的诸多中断之一。
- 肯尼迪长期以来对疫苗持怀疑态度，他监督了FDA和CDC的大规模重组，这一行动导致多名资深公共卫生官员和职业科学家被解雇。
- 公共卫生专家和国会议员对此次取消会议表示担忧，因为这一年度流程对帮助制造商为下一个流感季做准备而言极为罕见。
- FDA没有像往常一样举行公开顾问小组投票，而是内部确定了毒株选择，并直接向制造商发布建议。
- 该委员会通过审查疫苗安全性和有效性数据，并就疫苗是否应获得批准、更新或修改提出建议，为FDA提供咨询。
Christy Santhosh和Padmanabhan Ananthan在班加罗尔报道；Alan Barona编辑
我们的标准：[汤森路透信托原则., 新标签页打开]
FDA vaccine advisers to meet in March on flu strain selection
By Reuters
February 25, 2026 6:15 PM UTC Updated 1 hour ago
节点运行失败
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo [Purchase Licensing Rights, opens new tab]
- Companies
- [U.S. Food and Drug Administration]Follow
Feb 25 (Reuters) – The U.S. Food and Drug Administration said on Wednesday its advisory committee is set to meet on March 12 to discuss and make recommendations on the strain composition of flu vaccines for use during the 2026-2027 season.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up [here.]
- Last year, the meeting was canceled, one of many disruptions to vaccine-related advisory panels under health secretary Robert F. Kennedy Jr.
- Kennedy, a longtime vaccine skeptic, has overseen sweeping restructurings at the FDA and CDC, moves that have resulted in the removal of multiple senior public‑health officials and career scientists.
- Public health experts and lawmakers raised concerns about the cancellation, which was unusual for the annual process that helps manufacturers prepare for the next flu season.
- Instead of holding the usual public advisory panel vote, the FDA made the strain selection internally and issued recommendations directly to manufacturers.
- The committee advises the FDA by reviewing vaccine safety and effectiveness data and recommending whether vaccines should be approved, updated, or modified.
Reporting by Christy Santhosh and Padmanabhan Ananthan in Bengaluru; Editing by Alan Barona
Our Standards: [The Thomson Reuters Trust Principles., opens new tab]
发表回复